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Discovery of coding variants in genes that confer risk of neurodevelopmental disorders is an
important step towards understanding the pathophysiology of these disorders. Whole-
genome sequencing of 31,463 Icelanders uncovers a frameshift variant (E712KfsTer10) in
microtubule-associated protein 1B (MAP1B) that associates with ID/low IQ in a large pedigree
(genome-wide corrected P= 0.022). Additional stop-gain variants in MAP1B (E1032Ter and
R1664Ter) validate the association with ID and IQ. Carriers have 24% less white matter
(WM) volume (β=−2.1SD, P= 5.1 × 10−8), 47% less corpus callosum (CC) volume (β=
−2.4SD, P= 5.5 × 10−10) and lower brain-wide fractional anisotropy (P= 6.7 × 10−4). In
summary, we show that loss of MAP1B function affects general cognitive ability through a
profound, brain-wide WM deficit with likely disordered or compromised axons.
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ID refers to a group of aetiologically diverse conditions,resulting in below average cognitive abilities. Affected indivi-duals are typically identified in childhood due to delay in
developmental milestones. A formal diagnosis of ID is made
when an intelligence quotient (IQ) of less than 70, on a normal
distribution with a mean of 100 and standard deviation of 15, is
coupled with impairments in adaptive function including con-
ceptual, social and practical skills (APA URL)1. A full-scale IQ
(FSIQ) score is calculated from subtests grouped into two general
areas, verbal and performance related tasks, which can be dis-
crepant in some disorders2,3. While ID negatively affects
fecundity, de novo mutations maintain ID sequence variants in
the population4 and heritability estimates are higher for mild than
for severe ID5.
Numerous genes have been implicated across a wide spectrum
of syndromic and non-syndromic forms of ID and a significant
overlap noted with genes identified in other neurodevelopmental
disorders including ASD6. Large-scale next-generation sequen-
cing efforts of individuals with developmental disorders7, ID8,9
and ASD10 have made significant contributions to the under-
standing of their pathogenesis. Bioinformatics and functional
analyses have grouped some of the ID genes into common
pathways, representing regulation of transcription and transla-
tion, neurogenesis and neuronal migration and synaptic function
and plasticity11.
Utilising next-generation sequencing to search for variants in
genes important for brain development and function combined
with psychological assessment and brain structural traits in car-
riers, could provide a better understanding of the molecular
processes and neuronal connectivity underlying cognitive diver-
sity in neurodevelopmental disorders. Here we describe three
variants in the MAP1B gene, which truncate the protein, segre-
gating with ID and low IQ. Furthermore, carriers have sig-
nificantly less white matter (WM) volume and a decrease in
fractional anisotropy (FA), suggesting disordered or compro-
mised axons.
Results
Genome-wide scan for high-impact variants. We recruited an
extended pedigree with ID for cognitive phenotyping, brain
imaging and whole-genome sequencing (WGS) (Fig. 1a and
Supplementary Table 1). In this family there are five individuals
with diagnosed ID and three of their relatives, without a clinical
diagnosis, with IQ below 70. We applied a recently described
statistical procedure12 to estimate the intra-family association, of
genome-wide, rare, coding variants, with diagnosed ID or IQ
below 70. Only one variant, a frameshift variant causing pre-
mature truncation (E712KfsTer10) of MAP1B (Supplementary
Figure 1) was found to associate with the cognitive impairments
in this family (genome-wide corrected P= 0.022).
The E712KfsTer10 variant is carried by eight members of this
family, seven with ID or IQ below 70, and not found in any of
the other 31,463 WGS Icelanders. The eighth carrier (FAM1-
A1) is deceased, and so cognitive assessment could not be
performed. We note a noncarrier, in this family, with a
diagnosis of ID (FAM1-D4). As the E712KfsTer10 variant
results in cognitive impairments a carrier is likely to find a
partner with comparable cognitive abilities. This may intro-
duce, into the family, a mixture of rare and common markers
conferring risk of cognitive deficits.
MAP1B association with ID confirmed. We searched for addi-
tional MAP1B LoF variants in the 31,463 WGS Icelanders, of
whom 408 carry the diagnosis of ID, and found two stop-gain
variants, E1032Ter and R1664Ter (Supplementary Figure 1). The
E1032Ter variant was found in four individuals: three siblings
and their mother (Fig. 1b and Supplementary Table 1). Two of
the three siblings have atypical autism and a FSIQ below 70. Both
have higher verbal IQ (VIQ) than performance IQ (PIQ) and a
cognitive profile consistent with non-verbal learning disorder
(NVLD)13. The third sibling with a FSIQ of 79, reported having





























































































Fig. 1 Pedigree plots for MAP1B LoF carrier families. a Family 1 (FAM1)—E712KfsTer10 (c.2133delG), b Family 2 (FAM2)—E1032Ter (c.3094 G > T) and
c Family 3 (FAM3)—R1664Ter (c.4990 C > T). Squares are male, circles are female, diamonds are where gender is withheld, unfilled are unaffected, filled
with black are intellectual disability affected, half black and white are individuals without a clinical diagnosis but an IQ below 70, blue are Autism spectrum
disorder affected and yellow and white squares within the pedigree symbol indicates where it is most likely the initial MAP1B LoF mutation event occurred.
Below each icon is the subjects: alias; MAP1B LoF variant genotype; Full-scale IQ (Verbal IQ/Performance IQ) from WASIIS or WPPSI-R (FAM1-B1,-B3,-C1,-
C2,-D1,-D2,-D3; FAM2-H1,-H2,-J2; FAM3-K1,-K2,-L1 or FAM1-D5,-E1, respectively), or only Full-scale IQ reported from WISC-IV (FAM1-D4, FAM2-J1,-J3
and FAM3-M1), and corpus callosum (CC) volume (all individuals with structural MRI also have DTI except FAM1-C1). Refer to Supplementary Figure 2 for
a description of how the de novo event carriers were identified
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(VIQ higher than PIQ). The R1664Ter variant was found in two
individuals, a mother with a FSIQ of 92 (VIQ 105, PIQ 82) and
her daughter with a diagnosis of Asperger syndrome and a FSIQ
of 76 (Fig. 1c and Supplementary Table 1).
Hence, together the E1032Ter and R1664Ter variants are
carried by two ID cases and four of their relatives without an ID
diagnosis, but have an average IQ score of 81. Regressing the
allele carrier status, for either LoF variant, on the ID status or IQ
scores, further confirmed the association with LoF variants in
MAP1B (OR= 69.6, P= 4.9 × 10−4 and Effect (IQ score)=
−23.07, P= 1.4 × 10−3, respectively; Methods). This establishes
that LoF variants in MAP1B associate strongly with cognitive
impairments.
We also evaluated anthropometric traits including head
circumference, height and weight and found no association with
MAP1B LoF carrier status, after adjusting for relatedness (P=
0.16, 0.98, 0.56, respectively; Supplementary Table 2).
MAP1B variants in public databases. The three MAP1B LoF
variants, described here, have not been previously reported
(Supplementary Table 3) and were not observed in any of the
publicly available databases (Supplementary Table 4), which is
consistent with their rarity in Iceland. Furthermore, the Exome
Aggregation Consortium (ExAc, URL)14 estimated a very-high
probability of LoF intolerance for MAP1B, suggesting that LoF
mutations in MAP1B reduce fitness. However, LoF variants in
MAP1B are found in publicly available databases at a frequency of
1 in 10,000. ExAc also classify missense variants in MAP1B to be
under modest constraint. However, we do not observe any
MAP1B missense variants in individuals with ID or ASD.
Copy number variations spanning MAP1B have also been
reported in individuals where the most frequently described trait
is ID or developmental delay (Supplementary Table 5). A single
individual with a deletion spanning MAP1B was identified in a
sample of 157,065 Icelandic genotyped subjects. This deletion
carrier has severe ID (FAM4; Supplementary Table 1).
MAP1B carriers show general cognitive impairments. Overall,
the MAP1B LoF carriers (n= 13) have lower FSIQ than non-
carriers (P= 8.2 × 10−6, Table 1 and Supplementary Figure 3)
and a paired test revealed higher VIQ than PIQ (P= 0.042, two-
tailed, Student’s t-test), mainly due to the lower Block Design
subtest. A comparable difference between VIQ and PIQ scores
has been reported in disorders that include NVLD like symptoms,
including autism spectrum disorder (ASD)15, Fragile X syn-
drome13 and agenesis of corpus callosum (AgCC)16.
MAP1B LoF carriers and noncarrier relatives were adminis-
tered a battery of neuropsychological tests gauging aspects of
executive function, memory, attention and fluency17. As expected
from the IQ assessment, MAP1B LoF carriers performed poorly
on all cognitive tasks, in particular they recalled fewer words in
the letter fluency test (LF) and performed slower on the trail-
making test part A (TMT-A) (Table 2). Notably, MAP1B LoF
carriers also made more mistakes on the emotion recognition task
(ERT-Cor), a test of a form of social cognition, where comparable
impairments are described in ASD2, AgCC18 and NVLD13. The
MINI19 interview did not reveal any psychiatric disorders and
overall social and occupational functioning according to the
global assessment of functioning scale (GAF)20 gave comparable
scores for carriers and noncarriers (P= 0.69) (Table 2).
IQ and education polygenic score in MAP1B carriers. Com-
bining the effect sizes from a genome-wide association study
(GWAS) to generate a polygenic score (PGS) is beginning to play
a role in predicting differences in complex traits such as
intelligence21 and educational attainment22. We used summary
statistics from a recent GWAS for IQ23 and educational attain-
ment24 to determine the per-locus allele-specific weightings of
markers used to calculate a PGS for IQ (PGS-IQ) and educational
attainment (PGS-EDU), respectively (Methods and
References22,25). We compared the PGS-IQ and PGS-EDU in
MAP1B carriers (n= 13) to controls (n= 2164) and found no
significant difference (P= 0.20 and 0.82, respectively; Welch Two
Sample t-test) (Supplementary Figure 4 and Supplementary
Figure 5).
Brain structure affected by MAP1B variants. Brain MRI scans
were obtained of ten MAP1B LoF carriers. They have a smaller
corpus callosum (CC) and less brain-wide WM volume (β=
−2.4 SD, P= 5.5 × 10−10and β=−2.1 SD, P= 5.1 × 10−8,
respectively) than noncarriers (n= 949) (Table 3, Fig. 2 and
Supplementary Data 1). This corresponds to a CC and WM
volume deficit of 47 and 24%, respectively. Noncarrier relatives
(n= 5) have mean CC and WM volumes (−0.53 (SD 0.72) and
−0.88 (SD 0.97), respectively) indistinguishable from controls
(P= 0.22 and 0.043, respectively) (Supplementary Figure 6). The
association between theMAP1B LoF variants and smaller CC and
brain-wide WM volume is consistent with published findings in
mouse MAP1B knockouts, where AgCC, enlargement of the lat-
eral and third ventricles, and abnormal structures of the cortex,
cerebellum and hippocampus have been described26–28.
Apart from the reduced WM, significant differences were
observed in the grey matter (GM) surface area and volume of
several regions including decrease in right hemisphere (RH)
lateral occipital surface area, RH isthmus cingulate, thalamus and
left hemisphere (LH) postcentral surface area (Table 4 and Fig. 2).
The only region with more GM in carriers than noncarriers is the
RH insula (Table 4 and Fig. 2). The increased RH insula thickness
may be comparable with the recent description of deep
perisylvian/insular polymicrogyria on the right side, in a mother
and child, both with a truncating mutation in MAP1B
(Arg1106Ter), and diagnosed with periventricular nodular
heterotopia (PVNH)29.
Clinical MRI evaluation of MAP1B variant carriers. We per-
formed clinical MRI evaluation of the MAP1B LoF variant car-
riers described here and found nine to have periventricular
heterotopia symptoms consistent with PVNH (Supplementary
Table 1). Furthermore, most of the carriers had unusual/asym-
metric supratentorial brain anatomy, without any gross mal-
formation except in one MAP1B LoF carrier (FAM1-C1) with
isolated inferior vermian hypoplasia (Dandy-Walker variant). A
common neurological symptom of PVNH is epilepsy. However,
only one MAP1B LoF carrier, in our cohort, has diagnosed epi-
lepsy (FAM1-D3).
FA in reduced WM volume. Insight into WMmicrostructure can
be deduced from diffusion tensor imaging (DTI)30. Applying
tract-based spatial statistic (TBSS) analysis to whole-brain diffu-
sion data, from nine MAP1B LoF carriers compared to 181
controls, revealed an association with reduced FA in brain-wide
WM tracts (Fig. 3a). The lower FA observed in MAP1B LoF
carriers suggests that their axonal tracts are either of reduced
integrity or disordered arrangement. We also evaluated a subset
of the noncarrier controls with low CC or WM and found that
their FA was only affected in the densest part of the CC (Fig. 3b).
This suggests that the effect of the MAP1B LoF variants on FA
may be more profound than a smaller WM volume would
indicate.
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Truncated MAP1B protein is stable. To determine whether the
three MAP1B variants can produce a truncated MAP1B protein,
we transiently overexpressed plasmids, incorporating each of the
LoF mutations or wild-type MAP1B, in HeLa cells. We used
western blot analysis, with antibodies recognising either the N-
terminal or a V5 tag ligated to the C-terminal end ofMAP1B, and
detected bands in the expected sizes demonstrating that stable
truncated proteins are generated from all three LoF variants
(Fig. 4 and Supplementary Figure 7).
Discussion
We used a family-based approach to find a LoF variant inMAP1B
that associates with ID, GM and WM deficits and lower FA. The
family-based approach scores coding-sequence variants, propa-
gating in a pedigree, based on the predicted functional effect of
the variant and disease co-segregation likelihood ratio. We esti-
mated the genome-wide P-value using simulated segregation of
coding variants, from the founders of a large sample of WGS
Icelanders. Two additional stop-gain variants in MAP1B were
found, in two independent families, which confirmed the asso-
ciation with cognitive impairments. A PGS-IQ is not significantly
different in MAP1B carriers compared with controls, suggesting
that the LoF variants are responsible for the IQ impairment.
MAP1B (reviewed in Ref. 31) is a member of the microtubule
binding family of proteins important for axonal growth and
synapse maturation during brain development. MAP1B is pri-
marily expressed in the neuronal soma, dendrites and axons
where, during development, it is enriched in the axonal growth
cone. In the adult brain MAP1B expression remains high in areas
that retain plasticity, including olfactory bulb, hippocampus and
cerebellum. MAP1B undergoes post-translational modification
whereby it is cleaved into a heavy chain (HC) and a light chain
(LC1) (Supplementary Figure 1).
Each MAP1B chain has microtubule and actin-binding
domains that promote tubulin polymerisation and cross linking,
and while we only established that our LoF variants could pro-
duce stable truncated protein, in-vitro studies have shown that
similarly truncated MAP1B HC can promote microtubule
assembly32.
When phosphorylated, MAP1B maintains microtubules in a
dynamic state required for growth cone-mediated axonal elon-
gation. However, decreased MAP1B phosphorylation increases
microtubule stability, leading to axon branching33. The majority
of phosphorylation sites, regulating axonal growth and branching,
are located downstream of the E712KfsTer10 MAP1B variant34.
Loss of these sites, through MAP1B truncation, is therefore likely
to result in impaired elongation and increased branching as
Table 2 Cognitive assessment test scores for MAP1B LoF carriers compared with controls
Cognitive test n (MAP1B—Carriers/Controls) Mean (SD) (MAP1B—Carriers/Controls) β (95% CI) P
LMI&II 9/2230 65.9 (22.5)/68.6 (17.3) 0.3 (−0.5, 1.1) 0.45
LF 9/2221 16 (8.5)/29.3 (9.5) 1.2 (0.4, 2.1) 0.0037
CF 9/2224 17.2 (5.6)/22.0 (5.5) 0.8 (−0.01, 1.6) 0.053
Stroop 8/2218 48.8 (31.5)/26.6 (12.3) 1.0 (0.2, 1.9) 0.018
TMT 8/2207 82.8 (75.5)/44.8 (26.2) 0.8 (−0.1, 1.6) 0.065
Pers. err 9/2175 24.1 (15.2)/14.7 (12.3) 0.9 (0.1, 1.8) 0.031
SWM 9/2208 6.2 (5.1)/6.3 (7.2) 0.9 (0.1, 1.8) 0.026
RVIP 7/1964 0.9 (0.05)/0.9 (0.1) 0.9 (0.1, 1.8) 0.029
TMT-A 8/2218 42.2 (15.8)/29.6 (12.8) 1.2 (0.4, 2.1) 0.0046
Str-bl 8/2223 22.9 (4.1)/21.3 (4.4) 0.2 (−0.7, 1.0) 0.72
ERT-Cor 6/788 0.5 (0.2)/0.6 (0.1) 1.5 (0.5, 2.5) 0.0042
ERT-Lat 6/788 1912.3 (559.9)/1994.6 (680.2) 0.5 (−0.5, 1.5) 0.35
GAF 9/2153 80.7 (4.6)/80.9 (10.0) 0.2 (−0.7, 1.0) 0.69
The cognitive assessment values are unadjusted means and SD. For analyses the cognitive test scores were inverse normal transformed and adjusted for sex, age and age2. Cognitive test scores were
then shifted and scaled, resulting in controls having a mean of 0 and a standard deviation of 1. The cognitive test scores were arranged such that higher scores indicate greater impairment, in MAP1B LoF
carriers. The effects (β in SD) and P-values were calculated by comparing MAP1B LoF carriers (FAM1-B1,-C1,-C2,-D1,-D2,-D3, FAM2-H1,-J2, FAM3-L1) with controls using a generalised least-squares
regression with a variance–covariance matrix based on the kinship coefficient of each pair of individuals. See Methods for a description of the cognitive tests
LMI&II: logical memory subtest from the Wechsler Memory Scale III (WMS-III), LF: letter fluency from the controlled oral word association test (COWAT), CF: category fluency from the category
naming test, Stroop: name colour minus colour pad task, TMT: trail-making test (refers to part B minus part A), Pers. err.: perseverative error from the Wisconsin card-sorting test (WCST), SWM: spatial
working memory, RVIP: rapid visual information processing, TMT-A: trail-making test part A, Str-bl: stroop black letter, ERT-Cor: emotion recognition task-percentage correct, ERT-Lat: emotion
recognition task-mean response latency, SD: standard deviation, GAF: global assessment of functioning scale
Table 1 IQ scores for MAP1B LoF carriers compared with controls
IQ n (MAP1B—Carriers/Controls) Mean (SD) (MAP1B—Carriers/Controls) β (95% CI) P
Full-scale IQ 13/2226 68.3 (10.5)/102.1 (14.9) −1.6 (−2.3, −0.9) 8.2 × 10−6
Performance IQ 10/2226 66.4 (9.3)/99.8 (15.2) −1.6 (−2.4, −0.8) 6.4 × 10−5
Block design 9/1768 27.6 (5.8)/49.4 (10.5) −1.7 (−2.5, −0.9) 3.1 × 10−5
Matrix reasoning 9/1768 31.4 (7.5)/49.7 (10.0) −1.0 (−1.8, −0.2) 0.014
Verbal IQ 10/2226 74.5 (14.8)/103.5 (15.0) −1.2 (−2.0, −0.4) 0.0039
Vocabulary 9/1767 33.2 (11.8)/52.3 (9.5) −1.1 (−1.9, −0.3) 0.0082
Similarities 9/1768 34.0 (10.8)/51.5 (9.7) −1.0 (−1.8, −0.2) 0.016
The IQ tests values are unadjusted means and standard deviation (SD). For analyses, the IQ test scores were inverse normal transformed, then shifted and scaled, resulting in controls having a mean of 0
and a standard deviation of 1. Lower IQ scores represent greater impairment in MAP1B LoF carriers. The effects (β in SD) and P-values were calculated by comparing MAP1B LoF carriers (FAM1-B1,-C1,-
C2,-D1,-D2,-D3, FAM2-H1,-J2, FAM3-L1) with controls using a generalised least-squares regression with a variance–covariance matrix based on the kinship coefficient of each pair of individuals
SD: standard deviation
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neurites from mouse MAP1B null models demonstrate35 and is
recapitulated in studies where a MAP1B kinase, glycogen syn-
thase kinase 3β (GSK3β), a key regulator of axon growth and
branching, is inhibited36. This could explain the observed lower
FA in carriers as increased axonal branching or disordered
arrangement may appear as a decrease in WM tract directionality.
The three MAP1B LoF mutations all result in absence of the
LC1. LC1 has functions independent of the HC and separate from
its role during neuronal development31. For instance, LC1 reg-
ulates the addition and removal of AMPA-type glutamate
receptors at excitatory synapses, which forms one of the
mechanisms of synaptic plasticity37. By forming immobile com-
plexes, the LC1 traps AMPA receptors and limits intracellular
vesicular trafficking within the dendritic shaft. Hence, a LoF
mutation affecting the LC1 will prevent MAP1B from regulating
and restricting the access of AMPA receptors to dendritic spines
and the postsynaptic membrane. The MAP1B mutations,
E712KfsTer10, E1032Ter and R1664Ter are therefore likely to
affect the control of downregulation of synaptic transmission by
increasing the availability of circulating neurotransmitter recep-
tors37. Synaptic plasticity is accepted as the cellular basis of
learning and memory, and the loss of this regulatory action could,
in part, explain the carriers’ cognitive impairments.
Expression and function of MAP1B is regulated by products of
genes that when mutated, or lost, also result in neurodevelop-
mental disorders, including ID syndromes. A trinucleotide
expansion polymorphism in fragile X mental retardation 1
(FMR1), results in the Fragile X syndrome (FXS), a common
cause of ID6 and autism38. FMR1 codes for the fragile X mental
retardation protein (FMRP), an RNA-binding protein and
essential translation regulator of multiple genes during brain
development, including MAP1B38.
A recent study using FMR1-KO mice showed larger WM
volume overall, mostly due to the larger CC39. This is supported
by a human MRI study of adult males with FXS40. The loss of
FMRP in fragile X neurons and consequent reduction in its
translational suppression function leads to elevated MAP1B
expression38. This may be a contributing factor to the increased
WM, which is consistent with the phenotypes observed in the
FXS cases and the mouse FMR1-KO models.
Chromosome 2p15p16.1 deletion syndrome, which harbours
the zinc finger transcription factor BCL11A-L, is a rare genetic
disorder characterised by physical and neurodevelopmental
impairments, including ID, and structural brain abnormalities,
including CC hypoplasia41. Knockdown of BCL11A-L, down-
regulates expression of MAP1B and the axon-guidance receptor
DCC (deleted in colorectal cancer), and induces axon branching,
multi-axon formation, and dendrite outgrowth with suggestions
that BCL11A-L plays an important role in neural circuit forma-
tion during development42.
BCL11A-L and FMRP target numerous genes also important
for neuronal development, and their loss affects MAP1B expres-
sion in opposite direction. However, it is clear that under- or
over-connectivity can result in cognitive deficits and that MAP1B
is a critical intermediary, demonstrated by the loss of BCL11A-L
and FMRP.
Further research is required to unravel the effects of the
truncated MAP1B-HC and loss of one copy of LC1 on brain
development and synaptic plasticity. We have shown that LoF
mutations produce stable truncated MAP1B and that LoF carriers
develop both a neurological deficit and a cognitive impairment
phenotype providing a comprehensive description of a syndrome
involving MAP1B. LoF variants in MAP1B are found at a fre-
quency of ~1 in 10,000, in publicly available databases, which
places it within the range of the more common, single gene causes
of syndromic ID.
Methods
Study population and cognitive assessment. Samples, neuropsychological
assessment and questionnaire data were collected as part of studies approved by the
National Bioethics Committee in Iceland. Participants signed informed consent
before buccal swabs or blood samples were drawn. Personal identifiers were
encrypted by a third-party system overseen by the Icelandic Data Protection
Authority43.
Intellectual disability and autism diagnoses were assigned at the State
Diagnostic and Counselling Centre (SDCC) using ICD10 criteria. Refer to
Supplementary Table 1 for the Wechsler scale of intelligence available, from the
SDCC, for each participant.
Phenotypic assessment, at the Study Recruitment Centre, as applied
previously17, uses the Mini-International Neuropsychiatric Interview (M.I.N.I.)19
to assess psychiatric disorders and the Global Assessment of Functioning (GAF) to
assess social and occupational functioning. The Icelandic version of the Wechsler
Abbreviated Scale of Intelligence (WASIIS)44,45, which includes four subtests
(Vocabulary, Similarities, Block Design and Matrix Reasoning), was administered
to the MAP1B families and 1768 of the controls while another 458 controls were
tested with two subtests, Vocabulary and Matrix Reasoning, from the Wechsler
Adult Intelligence Scale (WAIS-III)46. As Icelandic norms are unavailable for
WAIS-III, these scores were combined with WASIIS scores using general cognitive
ability (an extracted g factor) as an indicator of the comparability of the two control
groups. We also applied the logical memory subtest (abbreviated LMI&II) from the
Wechsler Memory Scale III (WMS-III)47, the controlled oral word association test
(COWAT; here called LF)48, the category naming test (here called category
fluency)49, the Stroop test (name colour minus colour pad task abbreviated Stroop
and Stroop black letter)50, the trail-making test (TMT (refers to part B minus part
A) and TMT-A)51, the Wisconsin card-sorting test (WCST; perseverative error)52,
as well as the spatial working memory53, rapid visual information processing54 and
emotion recognition task (ERT; percentage correct and mean response latency55,56
Table 3 Brain white matter differences in MAP1B LoF carriers compared with controls
White matter MAP1B-FS Controls-FS β (95% CI) P
Corpus callosum—anterior—volume 431.3 (155.9) 900.2 (153.7) −2.6 (−3.4, −1.9) 1.9 × 10−11
Corpus callosum—posterior—volume 472.9 (141.4) 988.6 (156.7) −2.5 (−3.3, −1.8) 1.0 × 10−10
Corpus callosum—total—volume 1689.3 (426.4) 3210.3 (486.3) −2.4 (−3.2, −1.7) 5.5 × 10−10
LH—Cerebral white matter—volume 190965.3 (23104.5) 250084.3 (30115.5) −2.2 (−2.9, −1.4) 4.0 × 10−08
Total cerebral white matter—volume 382905.6 (46892.5) 502178.8 (60387.8) −2.1 (−2.9, −1.4) 5.1 × 10−08
RH—cerebral white matter—volume 191940.3 (23831.4) 252094.6 (30354.8) −2.1 (−2.9, −1.3) 6.8 × 10−08
Corpus callosum—central—volume 268.2 (56.6) 438 (87.7) −1.9 (−2.7, −1.1) 1.1 × 10−06
Corpus callosum—mid-posterior—volume 245.2 (60.4) 424.7 (92.3) −1.8 (−2.6, −1.0) 4.7 × 10−06
Corpus callosum—mid-anterior—volume 271.8 (80.5) 458.8 (103.6) −1.8 (−2.5, −1.0) 4.8 × 10−06
LH—white matter surface area 75187.5 (8576.7) 85866.9 (8321.5) −1.5 (−2.3, −0.8) 7.9 × 10−05
RH—white matter surface area 75488.3 (8865.8) 86285.6 (8411.9) −1.5 (−2.3, −0.8) 8.3 × 10−05
The MAP1B-FS and Control-FS are unadjusted mean and SD MRI white matter volume (mm3) and grey matter volume (mm3), surface area (mm2) and thickness (mm) values derived from FS.
Individuals’ FS values were inverse normal transformed and adjusted for sex, age, age2, scanner model and ICV where appropriate. The effect (β in SD) and P-value were calculated by comparing MAP1B
LoF carriers (n= 10; FAM1-B1,-C1,-C2,-D1,-D2,-D3, FAM2-H1,-J1,-J2, FAM3-L1) with controls (n= 949) using a generalised least-squares regression with a variance–covariance matrix based on the
kinship coefficient of each pair of individuals. See Supplementary Data 1 for the full list of 274 traits. Bonferroni significance level was set at 0.05/274= 1.8 × 10−4
LH: left hemisphere, RH: right hemisphere, SD: standard deviation, FS: FreeSurfer
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the last three are subtests of the Cambridge Neuropsychological Test Automated
Battery (http://www.cambridgecognition.com/).
As the ERT was not included in the previously published assessment17, it will be
briefly described here. The CANTAB ERT is a modified version of the Bristol
University Emotional Recognition Task55,57. A computer morphed face
(aggregated from 12 males) is presented on screen, for 200 ms, expressing one of
the six basic emotions (anger, disgust, fear, happiness, sadness or surprise)56 at a
level of intensity from 1 (least) to 15 (most). This is followed by a six-button
alternative forced-choice, whereby the participant is required to choose which
emotion was displayed on the previous image. Each emotion intensity combination
is presented either once, for a total of 90 images or in each of two sets of 90 images
for a total of 180 responses (6 emotions × 15 intensities × 2 rounds). Correct and
incorrect responses and response time latency was recorded for each emotion
intensity combination. ERT response time latency was averaged across the entire
set of responses for an overall mean response latency and ERT correct responses
were summed across all of the emotions and presented as a fraction of total
number of correct responses, per individual.
In total 13MAP1B LoF carriers had some form of Wechsler scale of intelligence
assessment. Where available, for the MAP1B LoF carriers, the WASIIS was used for
calculations, followed by WISC-IV and WPPSI-R (See Supplementary Table 1).
Where PIQ was compared with VIQ using a one-sided, paired t-test, age and
gender scaled IQ (mean of 100 and SD of 15) was used. Other IQ comparisons used
IQ data that was inverse normally transformed. Values from the other cognitive
tasks were inverse normally transformed, followed by adjustment for gender, age at
assessment and age2, based on controls. Tests were standardised so that controls
had a mean of zero and standard deviation of one and cognitive test scores
arranged so that higher scores indicated greater impairment. To take the
information on relatedness of the individuals into account, MAP1B LoF carriers
(n varies per task, see Tables 1 and 2) were compared with controls (n > 2,200, see
Tables 1 and 2) using generalised least-squares regression with a
variance–covariance matrix based on the kinship coefficient of each pair of
individuals (see Quantitative association replication and Reference58). To account
for multiple comparisons, the Bonferroni correction was used, giving a significance
threshold of P= 0.05/20= 2.5 × 10−3 (seven WASIIS tests and 13 cognitive tests).
We used RStudio (version 1.0.44; https://www.rstudio.com/) integrating R (version
3.3.2; https://www.r-project.org/) for data handling and some analyses, psych
package (version 1.16.12) for some summary statistics and ggplot2 (version 2.2.1)
to generate some of the figures.
Sequencing. Next-generation WGS, alignment and variant calling was carried out
as described in ref. 59. In brief, DNA samples, isolated from blood or buccal swabs,
were prepared using TruSeq DNA, TruSeq Nano or TruSeq PCR-Free kits as per
Illuminas instructions. DNA was fragmented, end-repaired, size-selected and
purified, followed by PCR enrichment and sequencing libraries were assessed for
quality and concentration. Following hybridisation of sequencing libraries to
flowcells using the Illumina cBot, Illumina GAIIx, HiSeq 2,000/2,500 or HiSeq X
























































Fig. 2 CC and WM volume differences in MAP1B LoF carriers compared with controls. a The colour scales refer to regions that are smaller (blue) or larger
(red/yellow) in MAP1B LoF carriers (n= 10) compared with controls (n= 949). See Tables 3 and 4 for details. The four brain aspects in the left of the
figure are from top left and clockwise: left hemisphere (LH) lateral surface, right hemisphere (RH) lateral surface, RH medial surface and LH medial surface.
The middle image is an axial slice with the front of the brain at the top of the figure and demonstrates the ubiquitous nature of the WM and GM effects; R is
right and L is left. The image on the right is a glass brain highlighting the significant reduction in WM in the corpus callosum. b Unadjusted corpus callosum
and cerebral WM volumes plotted against intracranial volume (ICV) from FreeSurfer (in mm3) for MAP1B LoF carriers (blue) compared with controls
(grey). Relative to the linear regression (diagonal line) the MAP1B LoF carriers have smaller CC and cerebral WM volumes than would be predicted from
their ICV
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followed by imaging and base-calling in real-time. All of the MAP1B carriers were
sequenced on the HiSeq X instrument. Reads were aligned to NCBI Build 38 of the
human reference sequence and then merged into a single BAM file, followed by
multi-sample variant calling performed with GenomeAnalysisTK (GATK) version
2.3.9.
Applied Biosystems BigDye Terminator v3.1 Cycle Sequencing Kit was used to
confirm MAP1B LoF carrier status. PCR and cycle sequencing reactions were
performed on MJ Research PTC-225 thermal cyclers. Applied Biosystems 3730xl
DNA analyzers were used for signal detection.
All positions reported are NCBI human genome build 38 unless otherwise
stated.
Family-based association analysis. We applied a recently described family-based
method12 to test rare coding-sequence variants for disease segregation within the
pedigree. In order to try and account for the extreme clustering of cases in the
pedigree we directed our search towards high-penetrance coding variants carried
by less than 30 whole-genome sequenced individuals. To test for association, we
create a scoring function based on the effect of the coding variant, as well as its co-
segregation with the disease, both inside and outside of the pedigree. Genome-wide
simulations are then used to provide significance estimates.
We used logistic regression, applying sex, year of birth, county of birth and
lifespan as covariates in the whole dataset, to estimate the probability of individual i
being affected: let Ai be the affection status of individual i and xi be his covariates,
then we estimate
fi ¼ logit p Aijxið Þð Þ;
or equivalently
p Aijxið Þ ¼
efi
1þ efi :
Our analysis tests particular variants, in a known set of carriers, distinct from
parametric linkage analysis which searches for linkage with unknown linkage
variants. However, comparable to parametric linkage60, the variant being tested has
an assumed effect.
We assume that the genetic effect parameter β, for the genotype gi of individual
i, affects penetrance as follows:
logit p Ai gi; xijð Þð Þ ¼ fi þ βgi
or equivalently
p Ai gi; xijð Þ ¼
efiþβgi
1þ efiþβgi :
We assumed gi to be either 0 or 1 given the dominant mode of inheritance
pattern of the cases. We used a peeling algorithm61, to calculate the likelihood of
the observed cases and controls, and so to estimate the genetic effect of the
supposed disease causing variant behind the familial clustering. We then obtained a
maximum likelihood estimate of the genetic effect β by maximising the likelihood
with a Broyden–Fletcher–Goldfarb–Shannon (BFGS) maximizer.
We then applied the optimal test statistic, to test whether a genetic variant is
causal or has no effect on disease, as stated by the likelihood ratio principle:
LLR ¼ log p A x;β¼β̂jð Þp A x;β¼0jð Þ ¼
P
i
log p Ai gi; xi; β ¼ β̂
  





































While affected and unaffected carriers have a positive and negative impact,
respectively, the log likelihood ratio terms are 0 for noncarriers. In order to avoid
blanket removal of variants not unique to the pedigree and to upweigh variants
Table 4 Brain grey matter differences in MAP1B LoF carriers compared with controls
Grey matter MAP1B-FS Controls-FS β (95% CI) P
RH—lateral occipital—area 3768.6 (336.8) 4813.9 (618.9) −2.1 (−2.9, −1.3) 1.1 × 10−07
RH—isthmus cingulate—volume 1690.8 (287.0) 2406.6 (426.9) −2.0 (−2.8, −1.3) 2.2 × 10−07
Right thalamus proper—volume 6056.4 (720.9) 7099.5 (756.2) −1.9 (−2.7, −1.2) 7.9 × 10−07
Total thalamus—volume 12720.9 (1506.2) 15006.4 (1608.0) −1.9 (−2.7, −1.2) 1.1 × 10−06
RH—superior parietal—volume 10269.2 (1554.5) 12473.5 (1572.3) −1.9 (−2.7, −1.1) 1.1 × 10−06
LH—postcentral—area 3433.9 (387.5) 4193.3 (502.1) −1.9 (−2.7, −1.1) 1.3 × 10−06
RH—insula—thickness 3.3 (0.1) 3.0 (0.2) 1.9 (1.1, 2.6) 1.9 × 10−06
RH—isthmus cingulate—area 697.0 (83.3) 962.5 (165.6) −1.9 (−2.6, −1.1) 2.0 × 10−06
LH—superior parietal—volume 10221.1 (1301.4) 12567.8 (1661.6) −1.8 (−2.5, −1.0) 4.9 × 10−06
RH—lingual—volume 5014.4 (689.2) 6379.8 (911.4) −1.8 (−2.6, −1.0) 5.3 × 10−06
LH—postcentral—volume 7424.0 (727.9) 9164.1 (1327.5) −1.7 (−2.5, −1.0) 9.3 × 10−06
Left thalamus proper—volume 6664.5 (838.1) 7906.9 (930.3) −1.7 (−2.5, −1.0) 1.1 × 10−05
RH—lateral orbito frontal—area 2247.6 (287.6) 2678.3 (312.4) −1.7 (−2.4, −0.9) 1.9 × 10−05
RH—rostral middle frontal—area 5043.1 (825.1) 5987.8 (778.0) −1.7 (−2.4, −0.9) 2.2 × 10−05
RH—lateral occipital—volume 9177.2 (1004.8) 11253.2 (1607.7) −1.6 (−2.4, −0.9) 2.4 × 10−05
LH—pericalcarine—area 1025.0 (208.3) 1431.4 (240.6) −1.6 (−2.4, −0.9) 2.5 × 10−05
RH—supramarginal—volume 8493.2 (1189.4) 9937 (1474.5) −1.6 (−2.4, −0.9) 3.5 × 10−05
LH—precuneus—volume 7665.6 (1201.7) 9202.4 (1259.4) −1.6 (−2.4, −0.8) 4.0 × 10−05
LH—superior parietal—area 4524.4 (632.9) 5480.6 (652.4) −1.6 (−2.3, −0.8) 5.3 × 10−05
LH—caudal middle frontal—volume 5046.0 (1235) 6265.4 (1168.2) −1.6 (−2.3, −0.8) 5.6 × 10−05
LH—caudal middle frontal—area 1872.9 (395.3) 2357.7 (386.6) −1.6 (−2.3, −0.8) 6.9 × 10−05
RH—supramarginal—area 3140.5 (543.8) 3717.1 (510.1) −1.6 (−2.3, −0.8) 8.6 × 10−05
LH—inferior temporal—area 2853.9 (423.8) 3477.8 (467.4) −1.5 (−2.3, −0.8) 8.8 × 10−05
LH—inferior parietal—area 3881.0 (729.8) 4648.8 (634.0) −1.5 (−2.3, −0.7) 1.3 × 10−04
RH—parsorbitalis—area 675.0 (98.6) 778.9 (107.8) −1.5 (−2.3, −0.7) 1.3 × 10−04
LH—inferior parietal—volume 10169.3 (1777.0) 12202.0 (1838.4) −1.5 (−2.3, −0.7) 1.4 × 10−04
RH—caudal middle frontal—area 1700.7 (328.7) 2199.7 (383.0) −1.5 (−2.3, −0.7) 1.5 × 10−04
RH—precentral—area 4096.8 (569.3) 4820.5 (574.8) −1.5 (−2.3, −0.7) 1.6 × 10−04
RH—lingual—area 2548.2 (274.5) 3175.1 (396.4) −1.5 (−2.2, −0.7) 1.7 × 10−04
The MAP1B-FS and Control-FS are unadjusted mean and standard deviation (SD) MRI white matter volume (mm3) and grey matter volume (mm3), surface area (mm2) and thickness (mm) values
derived from FreeSurfer (FS). Individuals’ FS values were inverse normal transformed and adjusted for sex, age, age2, scanner model and ICV where appropriate. The effect (β in SD) and P-value were
calculated by comparing MAP1B LoF carriers (n= 10; FAM1-B1,-C1,-C2,-D1,-D2,-D3, FAM2-H1,-J1,-J2, FAM3-L1) with controls (n= 949) using a generalised least-squares regression with a variance–
covariance matrix based on the kinship coefficient of each pair of individuals. See Supplementary Data 1 for the full list of 274 traits. Bonferroni significance level was set at 0.05/274= 1.8 × 10−4
LH: left hemisphere, RH: right hemisphere, SD: standard deviation, FS: FreeSurfer
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present in affecteds outside the pedigree, we counted carriers outside the family in
the score.
We define the score for marker m as
LLR mð Þ  log P coding effect of mð Þð Þ
We are only considering coding variants and −log (P (coding effect of m)) will be
2.96 higher for loss-of-function variants than moderate impact variants based on
the frequencies of such coding mutations62.
To estimate the significance of a variant we used genome-wide simulations,
sampling founders from a set of 30 K whole-genome sequenced Icelanders outside
of the pedigree and counting the number of times the highest score was equal to or
higher than the observed score. From 100,000 simulations a distribution of the
highest score for all markers in the genome could be generated and a genome-wide
P-value estimated from the fraction of simulations with scores greater than or equal
to the highest observed score. We took P < 0.05 to be significant.
Case control association replication. Logistic regression was used to test for
association between variants and disease, treating disease status as the response and
genotype counts (alleles from either LoF variant) as covariates (explanatory vari-
ables). We also included sex, county of birth, current age or age at death (first and
second order terms included), blood sample availability for the individual and an
indicator function for the overlap of the lifetime of the individual with the timespan
of phenotype collection as nuisance variables in the model.
Given genotype counts for n individuals, g1,ge,…,gnϵ{0,1,2}, their phenotypes y1,
y2,…,ynϵ{0,1} and a list of vectors of nuisance parameters x1,x2,…,xn, the logistic
regression model states that
Li α; β; γð Þ ¼ P yi ¼ 1 gi; xijð Þ
logit P yi ¼ 1 gi; xijð Þð Þ ¼ αþ βgi þ γTxi; for all i 2 f1; 2; :::; ng;
where α, β and γ are the regression coefficients and Li is the contribution of the i th
individual to the likelihood function; L α; β; γð Þ ¼ Qn
i¼1
Li α; β; γð Þ. It is then possible
to test for association based on the asymptotic assumption that the likelihood ratio












For the replication only whole-genome sequenced cases and controls were used;
of those FAM2-J1 and J3 are case carriers and FAM2-H1,-J2 and FAM3-L1 are
control carriers.
Quantitative association replication. A generalised form of linear regression was
used to test IQ for association with the variants.
The regression model assumes a normal distribution of the quantitative
measurements (y) with a mean that depends linearly on the expected allele (g) of
the variant being tested and a variance–covariance matrix proportional to the
kinship matrix:




2 ; i ¼ j
2kij; i≠j
(
is the kinship matrix as estimated from the Icelandic genealogical database.
Genetic analysis. Microarray genotyping and long-range phasing was described
previously59. Briefly, chip-typed samples are assayed with an Illumina bead chip at
deCODE genetics. Chip SNPs are excluded based on a number of quality criteria,
and samples with a call rate below 97% are not used.
Long-range phasing to determine parent of origin was achieved as outlined in
ref. 63. In brief, assigning the parent of origin was performed by identifying the
closest relatives who shared a haplotype with the proband. Parental origin was then
assigned to the two haplotypes of a proband on the basis of a computed score.
Computing IQ PGS and effect on IQ. Summary statistics from a recent GWAS for
IQ23 and educational attainment24 provided the per-locus allele-specific weightings
to calculate a PGS-IQ and PGS-EDU, respectively. The basic method used to
process the genotype data for Icelanders, including imputations based on full-
genome sequencing results, was described above and in Reference59. The markers
and methods used to compute the PGS-IQ and PGS-EDU have previously been
described for computing an educational attainment PGS in Kong et al22. A fra-
mework set of ∼600,000 high-quality SNPs (not including any of the MAP1B LoF
variants) covering the whole genome was used to compute PGS-IQ and PGS-EDU.
We adjusted for linkage disequilibrium using LDpred25. The linkage disequilibrium
between markers was estimated using the Icelandic samples. We used Welch two
sample t-test to compare PGS-IQ and PGS-EDU in MAP1B carriers (n= 13) to
controls (n= 2,164) in R (stats version 3.3.2).
a i ii biii i ii
Fig. 3 Diffusion (TBSS) data mapping from MAP1B LoF carriers compared with controls. Rows one, two, and three show, respectively, axial, coronal, and
sagittal aspects of brain (MNI coordinates: 1, −13, 19) where heat map (red/yellow) intensity represents a significant change in fractional anisotropy (FA).
aWe comparedMAP1B LoF carriers (n= 9) with three control groups (column i: normal range controls (n= 181), column ii: controls with small CC volume
(β <−1.5 SD, n= 15), and column iii: controls with small WM volume (β <−1.5 SD, n= 10)) and found the carriers to have significantly lower brain-wide FA
compared with all three control groups. b To determine whether a smaller CC volume generally leads to a decrease in FA, we compared the, column (i) 15
controls with smaller CC with 166 normal range controls and, column (ii) the ten controls with smaller WM with 160 normal range controls and found a
reduction in FA only in the densest part of the CC. Family wise error (FWE) corrected significance threshold of 0.05
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Magnetic resonance imaging acquisition. Magnetic resonance imaging (MRI),
previously described17,64 but summarised here, was performed on two 1.5 T whole
body scanners at Röntgen Domus Medica, a Philips Achieva and a Siemens
Magnetom Aera. Scans were done with a sagittal 3D fast T1-weighted gradient
echo sequence (Philips Achieva: repetition time (TR)= 8.6 ms, echo time (TE)=
4.0 ms, flip angle (FA)= 8°, 170 slices, slice thickness= 1.2 mm, acquisition
matrix= 192 × 192, field of view (FOV)= 240 × 240mm; Siemens Aera: repetition
time (TR)= 2400 ms, echo time (TE)= 3.54 ms, flip angle (FA)= 8°, 160 slices,
slice thickness= 1.2 mm, acquisition matrix= 192 × 192, field of view (FOV)=
240 × 240 mm). Ten MAP1B LoF carriers (on the Siemens Magnetom Aera) and
949 control subjects were scanned (257 with the Siemens Magnetom Aera and 692
with the Philips Achieva). Prior to FreeSurfer analyses, T1-weighted image data
was converted from DICOM to NIfTI format.
Diffusion tensor image (DTI) data was acquired on the Siemens Magnetom
Aera 1.5 T system. Diffusion-weighted echo planar imaging (EPI) was used. Three
series of 12 non-co-linear gradient diffusion-weighted images at b= 800 S/mm2
and one non-weighted (b= 0 S/mm2) image was acquired, for a total of 39 images.
The parameters for each image were as follows: TR= 8600 ms, TE= 60 ms,
60 slices, slice thickness= 2 mm, acquisition matrix= 120 × 120, FOV= 240 ×
240 mm, resulting in data acquired with a 2 × 2 × 2 mm voxel resolution.
Clinical MRI evaluation. Along with the sagittal 3D fast T1-weighted gradient
echo sequence, scans were also done with an axial proton density T2-weighted
turbo spin echo sequence (Siemens Aera: TR= 3000 ms, TE-1= 12 ms, TE-2=
96 ms, FA= 150°, 48 slices, slice thickness= 3 mm, acquisition matrix= 256 × 232,
FOV= 240 × 240mm). Prior to clinical assessment, T1- and T2-weighted image
data was converted from DICOM to NIfTI format. The neuroradiologist was
unaware of MAP1B LoF carrier status and was provided with equal numbers of
noncarriers, prior to evaluating symptoms of periventricular nodular heterotopia.
T1- and T2-weighted images were viewed using MRIcron version 12.12.2012
(http://www.mricro.com).
Surface-based morphometry. Segmentation and parcellation of the T1-weighted
image data was performed with FreeSurfer V5.3.0 software (http://freesurfer.net)65.
FreeSurfer automatically identifies cerebrospinal fluid (CSF), white matter (WM)66
and GM tissue in the brain and automatically segments and parcellates regions
according to predefined atlases; cortical regions according to the Desikan/Killiany
Atlas67 and subcortical regions according to the Fischl/Salat Atlas68. FreeSurfer
extracts region of interest (ROI) volumes (mm3) for all defined subcortical regions
and cortical thickness (mm), surface area (mm2) and volume (mm3) for all cortical
ROIs. This provided 104 Desikan/Killiany Atlas (times two for LH and RHs)
cortical values for analysis. Combined values for certain volumes were also created.
A total of 274 volumes, surface areas and thickness values were analysed (Sup-
plementary Data 1).
Volume, surface area and cortical thickness values were inverse normally
transformed, followed by adjustment for gender, age at scan, age2, scanner type and
where applicable ICV, based on data from controls only; intracranial volume (ICV)
was used as an adjustment variable for volume (except ICV was not adjusted for
itself) and surface area, but not for thickness. To take the information on
relatedness of the individuals into account, MAP1B LoF carriers (n= 10) were
compared with controls (n= 949) using generalised least-squares regression with a
variance–covariance matrix based on the kinship coefficient of each pair of
individuals (see Quantitative association replication and Ref. 58). To account for
multiple comparisons, the Bonferroni correction was used, giving a significance
threshold of P= 0.05/274= 1.8 × 10−4.
Diffusion tensor imaging. The diffusion-weighted data was preprocessed using
the FMRIB Software Library (FSL)69. First, FSL’s diffusion toolbox (FDT) was used
for eddy current and motion correction, where the eddy currents are corrected with
an affine registration to the b0 image and motion correction with a rigid body
registration to b0. Second, non-brain areas were removed from the analysis using
the BET tool70 from FSL. Finally, FDT was used to fit the tensors at each voxel and
create FA maps for each subject.
Tract-based spatial statistical analysis. Tract-based spatial statistics (TBSS) was
used to perform voxel-wise statistical analysis of the FA data71. FA data were
aligned into a common space using the nonlinear registration tool FNIRT72,73,
which uses a b-spline representation of the registration warp field74, for all subjects.
This was followed by creating a mean FA skeleton, which represents the centres of
all tracts common to the group, from the thinned, mean FA image. Data, resulting
from each subject’s aligned FA data projected onto the mean FA skeleton, were
then fed into voxel-wise cross-subject statistics.
Multiple regression models that included age and gender as covariates of no
interest were used to investigate the effect ofMAP1B on FA. A comparison between
controls and MAP1B subjects (CONTROL >MAP1B and MAP1B < CONTROL)
was performed. Additionally, MAP1B subjects were compared with CONTROLs
with lower WM volume and CONTROLs with smaller CC. Statistical significance
was assessed using FSL’s randomise function75 with the threshold-free cluster
enhancement (TFCE). The significance assessment was based on 5000 random
permutations and a corrected P < 0.05 was considered as significant.
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Fig. 4 Western blot of antibody binding to wild-type and truncated MAP1B proteins. a An image, from the Odyssey system, where the colour coded
infrared fluorescent signals from the 700 nm channel (V5 antibody signal—blue) and the 800 nm channel (MAP1B antibody signal—green) are taken from
the same blot; cyan indicates where both antibody signals overlap. See Supplementary Figure 7 for the individual V5 and MAP1B antibody signal greyscale
pictures. b A schematic diagram of what each band on the western blot represents in the context of protein size (heavy chain (HC), light chain 1 (LC1) and
truncated proteins). c A schematic diagram of truncated MAP1B and an indication of whether the anti-V5 or anti-MAP1B antibodies bind the protein
product. The wild-type HC is only recognised by the anti-MAP1B antibody (green), and the wild-type LC1 is only recognised by the anti-V5 antibody (blue),
while both anti-MAP1B and anti-V5 antibodies bind to all three truncated protein products as they contain both the MAP1B (amino acids 6-31) and V5 tags
(cyan bands in b). The red X indicates that the LC1 is not produced as a consequence of the MAP1B truncation. AB actin-binding domain, MTA microtubule
assembly helping site, putative, MTB microtubule-binding domain
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Generation of MAP1B plasmid variants. We obtained an ORF Flexi clone from
Promega (product ID FXC02218) that contained full-length MAP1B cDNA
(GenBank: NM_005909). From that clone, full-lengthMAP1B cDNA was amplified
by PCR primers F-5′ATGGCGACCGTGGTGGTG′3, R-5′CAGTTCAATCTTG
CATGCAGGG′3 and cloned into pcDNA3.1/V5-His TOPO vector (Invitrogen
K4800-01) following manufacturers protocol resulting in pcDNA3.1_MAP1B_WT.
Transformed TOP10 chemically competent cells (Invitrogen C4040-10) were pla-
ted on LB plates containing 100 µg/ml ampicillin. Colonies were expanded in LB
medium containing 100 µg/ml ampicillin. Plasmids were purified using Monarch
nucleic acid purification kit (New England Biolabs T1010L) following the manu-
facturers protocol. Plasmid sequence was confirmed by Sanger sequencing.
In order to generate MAP1B cDNA variants E1032Ter and R1664Ter the
pcDNA3.1_MAP1B_WT plasmid was used as a template. In short, a PCR reaction
was performed using the following primers E1032Ter (F-5′ATGGCGACCGTGG
TGGTG′3, R-5′CTCTCTGGCATCTTCAGCTTTG′3), and R1664Ter (F-5′ATG
GCGACCGTGGTGGTG′3, R-5′ACTGAAGTCCATAGCAAGGGAT′3) resulting
in a double stranded DNA fragment representing the entire pcDNA3.1 plasmid
and the first 1031, and 1663 amino acids of MAP1B for the E1032Ter, R1664Ter
variants, respectively. The STOP codon of the pcDNA3.1 plasmid was utilised
instead of the one encoded by the MAP1B variants in order to attach a 3′ V5-tag to
the protein variants in case MAP1B antibodies would not be able to recognise the
variant protein product.
To generate the E712KfsTer10 variant, we first mutated the pcDNA3.1_
MAP1B_WT plasmid using the Q5 site-directed mutagenesis kit (New England
BioLabs E0554S) and the following primers (F-5′AAGTTAAGAAGGAAGAGA
AG′3, R-5′CTTCTTGACTTCCTTTGG′3) generating pcDNA3.1_MAP1B_
WT_2133delG. With this mutagenesis, the MAP1B protein will be correct from
amino acid 1-711 followed by nine out of frame amino acids (KLRRKRRRK) plus a
termination codon. We subjected this mutagenesis product to a PCR to get a
template that contains the initiation codon of MAP1B in addition to the following
719 AA minus the stop codon using the following primers (F-5′ATGGCGACC
GTGGTGGTG′3, R-5′CTTCCTTCTTCTCTTCCTTCTTAAC′3). This template
was then cloned into pcDNA3.1 in frame with the V5 tag as described for the
MAP1B E1032Ter and R1664Ter mutations, resulting in pcDNA3.1_MAP1B_
E712KfsTer10. The sequences of pcDNA3.1_MAP1B_E712KfsTer10, pcDNA3.1_
MAP1B_E1032Ter, and pcDNA3.1_MAP1B_R1664Ter were confirmed by Sanger
sequencing.
Expression of MAP1B in cultured cells. One day prior to transfection, 320,000
HeLa cells (Public Health England 93021013) were seeded into each well of a 6-well
plate in 3 mL of DMEM medium (11995-065, ThermoFisher) supplemented with
10% foetal calf serum (ThermoFisher 10500-064) and 50 units/mL penicillin and
50 µg/mL streptomycin (ThermoFisher 15070-063). On the day of transfection,
media was replaced with the identical media as before without antibiotics. On the
day of transfection, for each transfected well, 2.5 µg of pcDNA3.1_MAP1B_WT,
pcDNA3.1_MAP1B_E712KfsTer10, pcDNA3.1_MAP1B_E1032Ter, or
pcDNA3.1_MAP1B_R1664Ter plasmids were diluted in 125 µL Opti-Mem med-
ium (ThermoFisher 31985- 047) and 5 µL of P3000 reagent (ThermoFisher L3000-
008). Next, 5 µL Lipofectamine 3000 (ThermoFisher L3000-008) was mixed with
125 µL of Opti-Mem. Subsequently, the diluted plasmid solution was mixed with
the Lipofectamine 3000 solution at a 1:1 ratio and incubated at room temperature
for 12 min before the addition of 250 µL of the combined solution to each trans-
fected well. Forty-eight hours post transfection, cell media was changed to full
media and 24 h later cells were harvested for analysis.
Western blot analysis. Wells were washed 2× with PBS and cells corresponding to
one well of a 6-well plate were lysed using 150 µl of RIPA buffer with 1:100 Halt
protease and phosphatase inhibitor cocktail (Thermo Scientific 78442). Lysates
were kept on ice for 10 min with agitation followed by sonication for 1 min
(Branson 2510). Lysates were spun down at 4 °C for 15 min at 14,000× g. Total
amount of protein lysates was estimated using BCA protein assay (Thermo Sci-
entific 23227). Samples were prepared using Novex Bolt LDS sample buffer (Life
technologies B0007) and Novex Bolt sample reducing agent (Life technologies
B0009) and run on NuPage 3–8% Tris-Acetate gel (ThermoFisher EAO375BOX).
Total protein amount per lane was 60 µg and HiMark Pre-stained HMW protein
standard (ThermoFisher Cat: LC5699) was used to estimate protein size. Gel was
run at a constant of 150 V for 1 hour. Proteins were transferred to a PVDF
membrane using wet blot transfer (mini trans blot BioRad) at a constant 70 V for
3 hours. Membranes were allowed to dry and then hydrated with MeOH and MQ
water before blotting. Membranes were blocked for 1 hour at room temperature
using 3% BSA in 1× TBS. Primary antibodies used were α-MAP1B (Santa Cruz sc-
365668) 1:500 (recognises amino acids 6-31) and α-V5 (R&D MAB8926) 1:1000
incubated in blocking buffer with the addition of 0.1% Tween overnight at+ 4 °C.
Secondary antibodies used were α-Rabbit 680RD (Li-Cor 926-68073) and α-Mouse
800CW (Li-Cor 926-32212) both 1:20,000 in TBST+ 0.01% SDS for 1 hour at
room temperature. After washing the membrane, it was allowed to dry and then
scanned using the Odyssey infrared imaging system (Li-Cor Biosciences). Anti-V5
and anti-MAP1B (amino acids 6-31) antibodies were visualised at 700 nm and 800
nm wavelengths, respectively.
URL. For American Psychiatric Association (APA), see https://psychiatry.org. For
Exome Aggregation Consortium (ExAc), see http://exac.broadinstitute.org/gene/
ENSG00000131711.
Data Availability. Data from publicly available databases (ExAc, gnomAD,
1000Genomes, NCBI-dbSNP/VarView, EVS-ESP, DECIPHER) and from the
Simons Simplex Collection approved researcher access, was presented in the main
text and supplementary material of this publication, but not used in any analyses.
The data used in the analyses for this publication are not publicly available due
to information, contained within them, that could compromise research
participant privacy. The authors declare that the data supporting the findings
of this study are available within the article, its Supplementary Information and
upon request.
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